Prescribing Opioids and Benzodiazepines: Strategies for Harm Reduction and Monitoring - 1 AOA Category 1-A Credit

Provided by an AOA-accredited Category 1 CME sponsor, this activity is eligible for AOA Category 1-A credit and includes instructor interaction; questions submitted by email will receive a response within 48 hours. Managing chronic pain with opioid therapy now requires more than checking boxes. It requires active, clinical risk management in a drug environment shaped by polysubstance use and synthetic adulterants. This activity provides comprehensive, evidence-based training aligned with the 2022 CDC Clinical Practice Guideline and grounded in a whole-person, biopsychosocial approach, helping osteopathic physicians protect patients while preserving function and therapeutic trust. Participants will learn to apply universal precautions with real-world precision, including effective use of Prescription Drug Monitoring Programs (PDMP) and clinically sound interpretation of urine drug testing (UDT), with attention to fentanyl and xylazine. The course emphasizes the practical “how-to” of responsible prescribing, including calculating morphine milligram equivalents (MME), documenting risk based on objective findings, recognizing opioid-induced hyperalgesia (OIH), and implementing slow, patient-centered tapering protocols that reduce destabilization and avoid preventable harm. The activity also prioritizes opioid-sparing strategies through multimodal analgesia and nonpharmacologic interventions that support functional restoration and long-term safety. This training responds to the evolving opioid crisis, including widespread illicit fentanyl exposure and emerging adulterants, as well as rising overdose risk in vulnerable populations. It closes common practice gaps such as outdated prescribing habits, misapplication of tapering guidance, and underuse of nonpharmacologic alternatives. By linking federal requirements, including the DEA MATE Act, to actionable clinical workflows and ethically grounded care, the course strengthens physician competence to balance beneficence and nonmaleficence in modern pain management.

This activity provides comprehensive, evidence-based training for clinicians managing chronic pain and opioid therapy, aligning with the 2022 CDC Clinical Practice Guidelines and a whole-person, biopsychosocial approach to patient care. Participants will master the critical transition from passive risk identification to active management in an opioid landscape increasingly defined by polysubstance use and synthetic adulterants.

The course moves beyond basic compliance by detailing the practical application of universal precautions, including a nuanced interpretation of urine drug testing (UDT) for fentanyl and xylazine, and effective use of Prescription Drug Monitoring Programs (PDMP) to prevent misuse. Key training focuses on the “how-to” of responsible prescribing: calculating safe morphine milligram equivalents (MME), implementing slow, patient-centered tapering protocols to avoid destabilization, and recognizing the physiological signs of opioid-induced hyperalgesia (OIH). The course also emphasizes opioid-sparing strategies, prioritizing multimodal analgesia and nonpharmacologic interventions as primary tools to support functional restoration and long-term safety.

The educational need for this course is driven by the emergence of the "Fourth Wave" of the opioid epidemic, characterized by the saturation of the drug supply with illicit fentanyl and xylazine, and the concurrent rise in overdose mortality among older adults and minority populations. This activity closes the professional practice gap stemming from outdated prescribing habits, the misapplication of tapering guidelines leading to patient harm, and the underutilization of non-pharmacologic alternatives. By linking federal mandates (DEA MATE Act) with actionable clinical workflows and a whole-person, ethically grounded approach to care, this training establishes the necessary competence to balance beneficence with non-maleficence in modern pain management.